Literature DB >> 20709228

Use of unregulated stem-cell based medicinal products.

.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20709228     DOI： 10.1016/S0140-6736(10)61249-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive.

Authors:  Romaldas Maciulaitis; Lucia D'Apote; Andrew Buchanan; Laura Pioppo; Christian K Schneider
Journal:  Mol Ther       Date:  2012-03       Impact factor: 11.454

2.  Regulation of stem cell therapies under attack in Europe: for whom the bell tolls.

Authors:  Paolo Bianco; Roger Barker; Oliver Brüstle; Elena Cattaneo; Hans Clevers; George Q Daley; Michele De Luca; Lawrence Goldstein; Olle Lindvall; Christine Mummery; Pamela G Robey; Clara Sattler de Sousa E Brito; Austin Smith
Journal:  EMBO J       Date:  2013-05-03       Impact factor: 11.598

3.  Regulations and guidelines governing stem cell based products: Clinical considerations.

Authors:  Bobby George
Journal:  Perspect Clin Res       Date:  2011-07

Review 4.  Characterisation of mesenchymal stromal cells in clinical trial reports: analysis of published descriptors.

Authors:  Alison J Wilson; Emma Rand; Andrew J Webster; Paul G Genever
Journal:  Stem Cell Res Ther       Date:  2021-06-22       Impact factor: 6.832
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.